bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
Authors: Basu Dipanjan , Lettan Robert , Damodaran Krishnan , Strellec Susan , Reyes-Mugica Miguel , Rebbaa Abdelhadi
Published: April 2023

PDF - 65K, Regulation of C19 activity by TDZD and rapamycin.
Supplementary Figure 2 from Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells
Authors: Sugiyama Kazuya , Kajiyama Hiroaki , Shibata Kiyosumi , Yuan Hong , Kikkawa Fumitaka , Senga Takeshi
Published: April 2023

PDF - 125K, (A) Mice were intraperitoneally injected with different amounts of recombinant adenovirus, and 2 days later, mice were sacrificed by cervical dislocation. The entire peritoneal cavity was fixed with 2% paraformaldehyde/0.2% glutaraldehyde intraperitoneally for 30 min. X-gal staining was performed, and the peritoneal cavity was opened for visual inspection. (B) X-gal-stained organs and mesothelial cells in the peritoneal cavity are shown.
Supplementary Figure 4 from Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
Authors: Basu Dipanjan , Lettan Robert , Damodaran Krishnan , Strellec Susan , Reyes-Mugica Miguel , Rebbaa Abdelhadi
Published: April 2023

PDF - 69K, Effect of siRNA-mediated TAZ knockdown on activation of EMT pathways.
Supplementary Figure 2 from Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
Authors: Basu Dipanjan , Lettan Robert , Damodaran Krishnan , Strellec Susan , Reyes-Mugica Miguel , Rebbaa Abdelhadi
Published: April 2023

PDF - 86K, Western blot density analysis.
Supplementary Figure 6 from Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Authors: De Robertis Alessandra , Valensin Silvia , Rossi Marco , Tunici Patrizia , Verani Margherita , De Rosa Antonella , Giordano Cinzia , Varrone Maurizio , Nencini Arianna , Pratelli Carmela , Benicchi Tiziana , Bakker Annette , Hill Jeffrey , Sangthongpitag Kanda , Pendharkar Vishal , Liu Boping , Mee Ng Fui , Wen Then Siew , Jing Tai Shi , Cheong Seong-Moon , He Xi , Caricasole Andrea , Salerno Massimiliano
Published: April 2023

PDF file - 112K, Average body weight graph.
Supplementary Figure 5 from Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Authors: De Robertis Alessandra , Valensin Silvia , Rossi Marco , Tunici Patrizia , Verani Margherita , De Rosa Antonella , Giordano Cinzia , Varrone Maurizio , Nencini Arianna , Pratelli Carmela , Benicchi Tiziana , Bakker Annette , Hill Jeffrey , Sangthongpitag Kanda , Pendharkar Vishal , Liu Boping , Mee Ng Fui , Wen Then Siew , Jing Tai Shi , Cheong Seong-Moon , He Xi , Caricasole Andrea , Salerno Massimiliano
Published: April 2023

PDF file - 98K, In vitro response of T98G cells to WNT signaling inhibition.
Supplementary Figure 4 from Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Authors: De Robertis Alessandra , Valensin Silvia , Rossi Marco , Tunici Patrizia , Verani Margherita , De Rosa Antonella , Giordano Cinzia , Varrone Maurizio , Nencini Arianna , Pratelli Carmela , Benicchi Tiziana , Bakker Annette , Hill Jeffrey , Sangthongpitag Kanda , Pendharkar Vishal , Liu Boping , Mee Ng Fui , Wen Then Siew , Jing Tai Shi , Cheong Seong-Moon , He Xi , Caricasole Andrea , Salerno Massimiliano
Published: April 2023

PDF file - 10K, SEN461 affects canonical WNT ligands mediated transcription.
Supplementary Figures 1-13 from A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide
Authors: Fan-Minogue Hua , Bodapati Sandhya , Solow-Cordero David , Fan Alice , Paulmurugan Ramasamy , Massoud Tarik F. , Felsher Dean W. , Gambhir Sanjiv S.
Published: April 2023

PDF file - 1.5 MB, Fig. S1. Scheme of the c-Myc activation sensor; Fig. S2. Optimal cell plating numbers for HTS format; Fig. S3. Optimal substrate concentration and imaging time for HTS format; Fig. S4. Robustness of the cell assay; Fig. S5. Plot of the occurrence frequency of compound classes for all the clean hits from five libraries; Fig. S6. The percent inhibition at 10�M of all the clean hits from the NCC library and the IC50 of all the clean hits from the Lopac library are plotted; Fig. S7. Plot of IC50 of all the clean hits from combined MS, BMI and BMF libraries; Fig. S8. The top three unexpected potent hits. The chemical structures of the three most potent hits that were not previously described to have an inhibitory effect on c-Myc are shown; Fig. S9A. Western blot analysis of lymphoma and sarcoma cells after NTZ treatment was performed using phospho c-Myc, c-Myc protein and �-actin antibodies; Fig. S9B. Dose dependent inhibition of phospho c-Myc by NTZ in different cancer cell lines; Fig. S10. Effect of NTZ on cell viability; Fig. S11. In vivo efficacy of NTZ in a SK-FST xenograft model; Fig. S12. Plot of the average body weight of NTZ or CMC treated group at indicated days after implantation.
Supplementary Figure 3 from Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Authors: De Robertis Alessandra , Valensin Silvia , Rossi Marco , Tunici Patrizia , Verani Margherita , De Rosa Antonella , Giordano Cinzia , Varrone Maurizio , Nencini Arianna , Pratelli Carmela , Benicchi Tiziana , Bakker Annette , Hill Jeffrey , Sangthongpitag Kanda , Pendharkar Vishal , Liu Boping , Mee Ng Fui , Wen Then Siew , Jing Tai Shi , Cheong Seong-Moon , He Xi , Caricasole Andrea , Salerno Massimiliano
Published: April 2023

PDF file - 20K, Comparative WNT transcriptional activity and growth inhibition with different compound AXIN stabilizers.
Supplementary Figure 2 from Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Authors: De Robertis Alessandra , Valensin Silvia , Rossi Marco , Tunici Patrizia , Verani Margherita , De Rosa Antonella , Giordano Cinzia , Varrone Maurizio , Nencini Arianna , Pratelli Carmela , Benicchi Tiziana , Bakker Annette , Hill Jeffrey , Sangthongpitag Kanda , Pendharkar Vishal , Liu Boping , Mee Ng Fui , Wen Then Siew , Jing Tai Shi , Cheong Seong-Moon , He Xi , Caricasole Andrea , Salerno Massimiliano
Published: April 2023

PDF file - 32K, Effects of different compound AXIN stabilizers on TNKS1 and TNKS2.
Supplementary methods and supplementary figures 1 through 4 from Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis
Authors: Voloshin Tali , Alishekevitz Dror , Kaneti Limor , Miller Valeria , Isakov Elina , Kaplanov Irena , Voronov Elena , Fremder Ella , Benhar Moran , Machluf Marcelle , Apte Ron N. , Shaked Yuval
Published: April 2023

Supplementary methods: Gene expression analysis (RT-PCR); MMP9 detection by gelatin; Scratch wound assay; Clodronate liposomes (clodrolip); Quantitation and visualization of microvessel density and vessel perfusion; Supplemental Figure 1: Tumor cell invasion and motility. Supplemental Figure 2: Invasion properties of tumor cells expressing IL-1R-I. Supplemental Figure 3: Tumor cell invasion and metastasis in IL-1β-deprived mice. Supplemental Figure 4: Relative perfusion area of 4T1 tumors, and the phenotype analysis of M1 and M2 macrophages.
Supplementary Figure 1 from Identification and Characterization of a Small-Molecule Inhibitor of Wnt Signaling in Glioblastoma Cells
Authors: De Robertis Alessandra , Valensin Silvia , Rossi Marco , Tunici Patrizia , Verani Margherita , De Rosa Antonella , Giordano Cinzia , Varrone Maurizio , Nencini Arianna , Pratelli Carmela , Benicchi Tiziana , Bakker Annette , Hill Jeffrey , Sangthongpitag Kanda , Pendharkar Vishal , Liu Boping , Mee Ng Fui , Wen Then Siew , Jing Tai Shi , Cheong Seong-Moon , He Xi , Caricasole Andrea , Salerno Massimiliano
Published: April 2023

PDF file - 94K, Consequences of inhibition of WNT signaling in glioblastoma cells: a less proliferative and less tumorigenic phenotype.
Supplementary Figure Legend from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Authors: Wang Jing , Pursell Natalie W. , Samson Maria Elena S. , Atoyan Ruzanna , Ma Anna W. , Selmi Abdelkader , Xu Wanlu , Cai Xiong , Voi Maurizio , Savagner Pierre , Lai Cheng-Jung
Published: April 2023

PDF file - 70K
Supplementary Figure 3 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Authors: Wang Jing , Pursell Natalie W. , Samson Maria Elena S. , Atoyan Ruzanna , Ma Anna W. , Selmi Abdelkader , Xu Wanlu , Cai Xiong , Voi Maurizio , Savagner Pierre , Lai Cheng-Jung
Published: April 2023

PDF file - 178K, Changes in live cell numbers induced by the treatment of CUDC-101, erlotinib, or vorinostat in conditions used in the migration and invasion assays.
Supplementary Table 2 from IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy
Authors: Ferté Charles , Loriot Yohann , Clémenson Céline , Commo Frederic , Gombos Andrea , Bibault Jean-Emmanuel , Fumagalli Ingrid , Hamama Saad , Auger Nathalie , Lahon Benoit , Chargari Cyrus , Calderaro Julien , Soria Jean-Charles , Deutsch Eric
Published: April 2023

XLSX file - 33K, Supplementary table 2: Overlapping pathways and differentially expressed genes (2 fold change, P<.05, Benjamini Hochberg adjusted) in H526 xenografts according to the treatment conditions: R1507 day 1,R1507 day 7, R1507-CDDP day 7 and R1507-IR day 7. The overlap significance (P value) between the differentially expressed probe sets and the curated molecular signature databases were computed using Fisher exact tests.
Supplementary Table 1 from IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy
Authors: Ferté Charles , Loriot Yohann , Clémenson Céline , Commo Frederic , Gombos Andrea , Bibault Jean-Emmanuel , Fumagalli Ingrid , Hamama Saad , Auger Nathalie , Lahon Benoit , Chargari Cyrus , Calderaro Julien , Soria Jean-Charles , Deutsch Eric
Published: April 2023

XLSX file - 35K, Effect of R1507, Cisplatin, IR and their combinations on the RTV5.
Supplementary Figures 1 - 6 from Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Authors: Ihnen Maike , zu Eulenburg Christine , Kolarova Teodora , Qi Jing Wei , Manivong Kanthinh , Chalukya Meenal , Dering Judy , Anderson Lee , Ginther Charles , Meuter Alexandra , Winterhoff Boris , Jones Siân , Velculescu Victor E. , Venkatesan Natarajan , Rong Hong-Mei , Dandekar Sugandha , Udar Nitin , Jänicke Fritz , Los Gerrit , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 603K, Supplemental Figure S1: Gene maps of the BRCA1 (A) and BRCA2 (B) CpG islands examined with bisulfite pyrosequencing. Supplemental Figure S2: Anchorage independent growth inhibition at 1μM rucaparib in soft agar. Of the 39 tested ovarian cancer cell lines 22 formed colonies in soft agar. Supplemental Figure S3: Microarray hybridizations of the cell line panel were performed using the Agilent Whole Human Genome 4X44K array chip.Supplemental Figure S4: Chemical structures of compounds used for the drug interaction studies.Supplemental Figure S5: A multivariate ANOVA model (accounting for type of chemotherapy, cell line, and drug concentration as single factors) indicates that the drug combination effects differed significantly between individual chemotherapeutic agents (P=0.010). Supplemental Figure S6: A multivariate ANOVA model (accounting for type of chemotherapy, cell line, and drug concentration as single factors) indicates that the best combination effect was achieved at lower topotecan (0.031 μM) and rucaparib (0.625 μM) drug concentrations (P=0.018).
Supplementary Figures 1 - 6, Table 1 from A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo
Authors: Chen Thomas C. , Cho Hee-Yeon , Wang Weijun , Barath Manasi , Sharma Natasha , Hofman Florence M. , Schönthal Axel H.
Published: April 2023

PDF file - 320K, Supplementary Table S1: Drug sensitivities of cells transfected with MGMT cDNA; Supplementary Figure S1: Chemical structure of T-P; Supplementary Figure S2: Colony formation after drug treatment; Supplementary Figure S3: Histopathological evaluation following chronic T-P treatment; Supplementary Figure S4: Drug effects on intracranial tumor growth; Supplementary Figure S5: Body weight changes of mice over time; Supplementary Figure S6: Drug effects and body weight changes in mice.
Supplementary Figure S2 from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 1.5 MB, Reversed-phase HPLC analyses for cleavage of ME-capped CL2E-SN-38 by cathepsin-B
Supplementary Figure Legends from A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo
Authors: Chen Thomas C. , Cho Hee-Yeon , Wang Weijun , Barath Manasi , Sharma Natasha , Hofman Florence M. , Schönthal Axel H.
Published: April 2023

PDF file - 72K
Supplementary Figure S1 from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 2 MB, Immunohistological assessment of the distribution of CEACAM6 and Trop-2 in formalin-fixed, paraffin-embedded xenografts of human cancer cell lines
Supplementary Table 3 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Authors: Ning Yan , Gerger Armin , Zhang Wu , Hanna Diana L. , Yang Dongyun , Winder Thomas , Wakatsuki Takeru , Labonte Melissa J. , Stintzing Sebastian , Volz Nico , Sunakawa Yu , Stremitzer Stefan , El-Khoueiry Rita , Lenz Heinz-Josef
Published: April 2023

PDF - 91KB, Other PLS3 polymorphisms and outcome in patients with stage II or III colon cancer by sex (Training set).
Supplementary Figure Legends from Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Authors: Govindan Serengulam V. , Cardillo Thomas M. , Sharkey Robert M. , Tat Fatma , Gold David V. , Goldenberg David M.
Published: April 2023

PDF file - 66 KB
Supplementary Table 1 from Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy
Authors: Ning Yan , Gerger Armin , Zhang Wu , Hanna Diana L. , Yang Dongyun , Winder Thomas , Wakatsuki Takeru , Labonte Melissa J. , Stintzing Sebastian , Volz Nico , Sunakawa Yu , Stremitzer Stefan , El-Khoueiry Rita , Lenz Heinz-Josef
Published: April 2023

PDF - 85KB, Primer sequences and region of Plastin polymorphisms.
Supplementary Figure Legends from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 66K, Legends for Supplementary Figures.
Supplementary Figure 3 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 118K, Reported targets of leelamine do not play role in leelamine mediated cell death.
Supplementary Figure 2 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 117K, Leelamine mediated cell death does not involve de-novo protein synthesis or leakage of proteases from lysosomes.
Supplementary Table 3 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 42KB, Comparison of bliss scores in p53 genetically matched HCT116 cell lines.
Supplementary Table 1 from Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Authors: Jin Bei , Ding Ke , Pan Jingxuan
Published: April 2023

PDF file - 43KB, The primers are listed.
Supplementary Figure 4 from Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Authors: Jin Bei , Ding Ke , Pan Jingxuan
Published: April 2023

PDF file - 158KB, Peripheral blood cell counts of ASM/MCL mice.
Supplementary Figure and Table Legend from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 66KB, A detailed description of the supplementary figures and tables.
Supplementary Figure 2 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 46KB, GNE-900 can potentiate the activity of gemcitabine, SN-38 and TMZ.
Supplementary Figure Legends from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 95KB
Supplementary Table 2 from Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro
Authors: Hu Jinsong , Van Valckenborgh Els , Xu Dehui , Menu Eline , De Raeve Hendrik , De Bryune Elke , Xu Song , Van Camp Ben , Handisides Damian , Hart Charles P. , Vanderkerken Karin
Published: April 2023

PDF file - 116 KB, Combination index analysis of TH-302 combined with bortezomib at a non-constant ratio in MMS1 cells.
Supplementary Figure 3 from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 681KB, STRING Gene cluster analysis.
Supplementary Figure 1 from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 185KB, MGMT-expressing GIC are highly resistant to TMZ.
Supplementary Table 4C from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

XLSX - 736K, Table S4C. Differentially expressed genes between Control Vs. BIO treated cells.
Supplementary Figure 3 from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Figure 3: (A) NSCLC U-1810 cells or diploid fibroblasts WI-38 were treated with DMSO, 1 or 2 (3 microM) for 48 h. Cisplatin (20 microM, 72 h) treated U-1810 cells were used as a positive control for induction of apoptotic morphology. Nuclear morphology of cells was examined after fixation in 4 % paraformaldehyde and staining with DAPI. Pictures showing nuclear morphology (magnification 60x, the scale bar equals 25 microm). Arrows show apoptotic morphology of the cell nuclei. (B) NSCLC U-1810 cells were treated with 3 microM concentration of compound 2 and cleavage of caspase-3, caspase-9 or PARP was examined after 24, 48 and 72 h. β actin was used to visualize equal loading.
Supplementary Figure 1 from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Figure 1: Separation of Cribrochalina vasculum</i> crude extract and isolation of compounds 1 and 2. (A) The crude extract (43 g) was separated by reversed phase flash chromatography using a gradient of solvents, from 100 % water through 100 % methanol and then to 100 % ethyl acetate. Fraction 10 was further separated twice on a size exclusion Sephadex LH-20 column using 1:1 mixture of chloroform:methanol as mobile phase. The semi-pure fractions from the second Sephadex LH-20 column (fractions 8-11) were combined and separated on a reversed phase HPLC column (semi-preparative YMC C-8) with a mixture of 40:51:9 acetonitrile:methanol:water as an isocratic mobile phase. Two pure substances, (3S)-icos-4E-en-1-yn-3-ol (1) (tR</sub> 41.8 min, 70.1 mg) and (3S)-14-methyldocos-4E-en-1-yn-3-ol (2) (tR 67.0 min, 109 mg) were obtained. (B) HPLC chromatogram of the semi-pure fractions 8-11 from the second Sephadex LH-20 column revealed two substances; (3S)-icos-4E-en-1-yn-3-ol (1) and (3S)-14-methyldocos-4E-en-1-yn-3-ol (2). (C) SMB MS fragmentation of compound 2 showed a loss of 14 mass units for each carbon except for C-14 where a loss of 28 mass units was observed, indicating that the branched methyl substituent is situated on C-14.
Supplementary Figure Legends, Supplementary Table Legends, and Supplementary Tables 1 through 7 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Authors: Fritsch Christine , Huang Alan , Chatenay-Rivauday Christian , Schnell Christian , Reddy Anupama , Liu Manway , Kauffmann Audrey , Guthy Daniel , Erdmann Dirk , De Pover Alain , Furet Pascal , Gao Hui , Ferretti Stephane , Wang Youzhen , Trappe Joerg , Brachmann Saskia M. , Maira Sauveur-Michel , Wilson Christopher , Boehm Markus , Garcia-Echeverria Carlos , Chene Patrick , Wiesmann Marion , Cozens Robert , Lehar Joseph , Schlegel Robert , Caravatti Giorgio , Hofmann Francesco , Sellers William R.
Published: April 2023

PDF - 129K, Legends for Supplementary Figures 1 through 4 and Supplementary Tables 1 through 7. Supplementary Table 1. Determination of NVP-BYL719 in vitro effects on human protein kinases. Supplementary Table 2. Activity profile of NVP-BYL719 in the Invitrogen Kinase panel. Supplementary Table 3. Activity profile of NVP-BYL719 in the Ambit Kinase panel. Supplementary Table 4. NVP-BYL719 Kd (nmol/L) determination in the Ambit Kinase panel for the hits found to be inhibited >90%. Supplementary Table 5. NVP-BYL719 anti-tumor effects in diverse cancer cell line-derived xenograft models. Supplementary Table 6. CCLE cell lines responsive to NVP-BYL719. Supplementary Table 7 Anti-tumor effect of NVP-BYL719 in patient-derived xenograft models carrying PIK3CA genetic alterations.
Supplementary Materials and Methods and Supplementary Figures 1 through 3 from Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6–Induced Experimental Prostate Cancer Metastases Formation
Authors: Gu Lei , Talati Pooja , Vogiatzi Paraskevi , Romero-Weaver Ana L. , Abdulghani Junaid , Liao Zhiyong , Leiby Benjamin , Hoang David T. , Mirtti Tuomas , Alanen Kalle , Zinda Michael , Huszar Dennis , Nevalainen Marja T.
Published: April 2023

PDF - 295K, Suppl. Fig. 1. Autocrine IL-6 induces metastatic colonization of CWR22Rv1 human PC cells in the livers of mice in an experimental metastases assay. Figure 2. IL-6 induces a migratory phenotype in CWR22Rv1 PC cells. Suppl. Fig. 3. Pharmacological Jak1/2 inhibitor AZD1480 suppresses IL-6-activated Stat3 signaling in CWR22Rv1 PC cells and IL-6-induced migratory PC cell phenotype.
Supplementary Figure 4 from Coordinate Hyperactivation of Notch1 and Ras/MAPK Pathways Correlates with Poor Patient Survival: Novel Therapeutic Strategy for Aggressive Breast Cancers
Authors: Mittal Suruchi , Sharma Ankur , Balaji Sai A. , Gowda Manju C. , Dighe Rajan R. , Kumar Rekha V. , Rangarajan Annapoorni
Published: April 2023

Supplementary Figure 4: Breast cancer cell lines were subjected to sphere formation in the presence of anti-Notch1 MAb602.101 (10microg/ml), 10microM MAPK inhibitor (PD98059), combination of MAb602.101 and PD98059 and appropriate controls (IgG and DMSO). After a week cells were dissociated and subjected for secondary sphere formation in the absence of any treatments. Photomicrographs represent phase contrast images of secondary spheres formed by MDA-MB-231 and BT-474 cells; magnification 10x.
Supplementary Figure 3 from Coordinate Hyperactivation of Notch1 and Ras/MAPK Pathways Correlates with Poor Patient Survival: Novel Therapeutic Strategy for Aggressive Breast Cancers
Authors: Mittal Suruchi , Sharma Ankur , Balaji Sai A. , Gowda Manju C. , Dighe Rajan R. , Kumar Rekha V. , Rangarajan Annapoorni
Published: April 2023

Supplementary Figure 3: Breast cancer cell lines (A) BT-474, (B) MCF-7 and (C) MDA-MB-231 were treated with anti-Notch1 MAb (602.101), MAPK inhibitor (PD98059), combination of MAb602.101 and PD98059 and appropriate controls (IgG and DMSO) and cell viability was assessed by MTT assay.
Supplementary Figure 2 from Coordinate Hyperactivation of Notch1 and Ras/MAPK Pathways Correlates with Poor Patient Survival: Novel Therapeutic Strategy for Aggressive Breast Cancers
Authors: Mittal Suruchi , Sharma Ankur , Balaji Sai A. , Gowda Manju C. , Dighe Rajan R. , Kumar Rekha V. , Rangarajan Annapoorni
Published: April 2023

Supplementary Figure 2: BT474 cells treated with anti-Notch1 MAb 602.101 (10microg/ml) and MEK inhibitor PD98059 (10microM), alone (A and C respectively) or together (D), for 48 hrs were subjected to real time PCR analysis using specified primer sets; treatment with IgG and DMSO served as controls. (B) MDA-MB-231 and HCC-1806 cells were treated with PD98059 (10 microM) for 48 hours and subjected to immunoblot analysis for the specified proteins.
Supplementary Figure 1 from Coordinate Hyperactivation of Notch1 and Ras/MAPK Pathways Correlates with Poor Patient Survival: Novel Therapeutic Strategy for Aggressive Breast Cancers
Authors: Mittal Suruchi , Sharma Ankur , Balaji Sai A. , Gowda Manju C. , Dighe Rajan R. , Kumar Rekha V. , Rangarajan Annapoorni
Published: April 2023

Supplementary Figure 1: A) Photomicrographs show representative immunohistochemical staining for the expression of cleaved Notch1 and pErk1/2 in breast cancer patient samples based on which they were further sub-divided into clNotch1highpErkhigh and the 'rest' (including, clNotch1lowpErklow, clNotch1highpErklow and clNotch1lowpErkhigh ) categories. B) Representative images for the expression of stemness markers CD44, Oct-4 and Nanog in TNBC patient samples as determined by immunohistochemistry analysis.
Supplementary Figure 5 from Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis
Authors: Petruccelli Luca A. , Pettersson Filippa , del Rincón Sonia V. , Guilbert Cynthia , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

PDF file - 1130K, Vorinostat induces apoptosis in NB4 and Kasumi cells, and induction of PML-RARα and AML1-ETO in PR9 and U937-A/E cells.
Supplementary Figures 1 through 8 from Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma
Authors: Agarwal Jasmin R. , Wang Qiuju , Tanno Toshihiko , Rasheed Zeshaan , Merchant Akil , Ghosh Nilanjan , Borrello Ivan , Huff Carol Ann , Parhami Farhad , Matsui William
Published: April 2023

PDF - 177K, Figure S1. LXR expression in myeloma cell lines. Figure S2. Induction of LXR target genes by non-steroidal LXR agonists. Figure S3. Effects of LXR agonists on clonogenic myeloma growth. Figure S4. Impact of T0901317 on myeloma cell growth and survival. Figure S5. Dose-response relationships of T0901317 in U266 cells. Figure S6. Gene knock-down by siRNA. Figure S7. Effects of LXR agonists on myeloma tumor initiating cells. Figure S8. In vivo activation of LXR target genes.
Supplementary Figures 1 through 10 and Supplementary Tables 1 through 3 from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Authors: Fitzgerald Jonathan B. , Johnson Bryan W. , Baum Jason , Adams Sharlene , Iadevaia Sergio , Tang Jian , Rimkunas Victoria , Xu Lihui , Kohli Neeraj , Rennard Rachel , Razlog Maja , Jiao Yang , Harms Brian D. , Olivier Kenneth J. , Schoeberl Birgit , Nielsen Ulrik B. , Lugovskoy Alexey A.
Published: April 2023

PDF - 711K, Supplemental Figure S1. Schematic representation of components of IGF-1R/ErbB3 merged mechanistic signaling model. Supplemental Table S1. Mean ligand-stimulated pAKT (S473) levels (A) or simulated levels (B) in BxPC-3, AdRr and MCF7 cells that were used to generate 3D contour plots in Figure 1A. Supplemental Figure S2. Western blots used to generate bar graphs in Figures 1, 3, & 4. Supplemental Figure S3. MM-141 is selective for IGF-1R and ErbB3, and is cross-reactive to relevant toxicology species. Supplemental Table S2. MM-141 is more potent than monospecific antibodies at inhibition of single ligand-induced pAKT (Ser473) signaling. Supplemental Figure S4. MM-141 does not promote basal signaling. Supplemental Figure S5. Generation of isogenic BxPC-3 cell lines with stable knockdown of IGF-1R or ErbB3. Supplemental Table S3. Mean pAKT (S473) levels in engineered BxPC-3 cells that were used to generate 3D contour plots in Figure 3A. Supplemental Figure S6. MM-141 maintains activity over a broad range of receptor profiles. Supplemental Figure S7. Mechanistic model can recapitulate signal inhibition properties of MM-141. Supplemental Figure S8. Pharmacokinetic properties of MM-141. Supplemental Figure S9. MM-141 controls gemcitabine-induced network adaptation. Supplemental Figure S10. MM-141 controls expression of IGF-1R and ErbB3-interacting RTKs.
Supplementary Figure Legends from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Authors: Fitzgerald Jonathan B. , Johnson Bryan W. , Baum Jason , Adams Sharlene , Iadevaia Sergio , Tang Jian , Rimkunas Victoria , Xu Lihui , Kohli Neeraj , Rennard Rachel , Razlog Maja , Jiao Yang , Harms Brian D. , Olivier Kenneth J. , Schoeberl Birgit , Nielsen Ulrik B. , Lugovskoy Alexey A.
Published: April 2023

PDF - 91K, Supplementary Figure Legends.
Supplementary Figures 1 - 4 from ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer
Authors: Zinn Rebekah L. , Gardner Eric E. , Marchionni Luigi , Murphy Sara C. , Dobromilskaya Irina , Hann Christine L. , Rudin Charles M.
Published: April 2023

PDF file - 927K, Supplemental Figure 1 (associated with Figure 2). Expression of IGF-1R, IR, ERK, and AKT does not correlate with sensitivity to OSI-906 in SCLC cell lines. Supplemental Figure 2 (associated with Figure 4). Treatment with OSI-906 results in inhibition of phosphorylated IGF-1R and Akt, but not phosphorylated ERK, in both sensitive and resistant cell lines. Supplemental Figure 3. Inhibition of MEK or overexpression of an active MEK mutant does not alter SCLC sensitivity to OSI-906. Supplemental Figure 4. OSI-906 treatment induces cell cycle arrest in sensitive cell lines.
Supplementary Table 1 from Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients
Authors: Singer Josef , Fazekas Judit , Wang Wei , Weichselbaumer Marlene , Matz Miroslawa , Mader Alexander , Steinfellner Willibald , Meitz Sarah , Mechtcheriakova Diana , Sobanov Yuri , Willmann Michael , Stockner Thomas , Spillner Edzard , Kunert Renate , Jensen-Jarolim Erika
Published: April 2023

PDF - 210K, Can225IgG heavy and light chain amino acid sequences.
Supplementary Figure Legends and Supplementary Figures 1 through 5 from Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients
Authors: Singer Josef , Fazekas Judit , Wang Wei , Weichselbaumer Marlene , Matz Miroslawa , Mader Alexander , Steinfellner Willibald , Meitz Sarah , Mechtcheriakova Diana , Sobanov Yuri , Willmann Michael , Stockner Thomas , Spillner Edzard , Kunert Renate , Jensen-Jarolim Erika
Published: April 2023

PDF - 446K, Figure S1. Purification of can225IgG from cell culture supernatant is efficient with Protein G, but not with Protein A. Figure S2. Elution of can225IgG from Protein G columns at a low pH does not affect integrity of the antibody. Figure S3. Binding of can225IgG to the cell lines CF33, CF41, TLM-1 and BT474 in FACS. Figure S4. Can225IgG shows a slightly lower binding affinity towards canine EGFR, compared with human EGFR. Figure S5. Staining of EGFR+ cell line and canine mammary carcinoma section by can225IgG.
Supplementary Information from Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons
Authors: Gmeiner William H. , Reinhold William C. , Pommier Yves
Published: April 2023

Supplementary Information from Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons
Supplemementary Materials and Methods from Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients
Authors: Singer Josef , Fazekas Judit , Wang Wei , Weichselbaumer Marlene , Matz Miroslawa , Mader Alexander , Steinfellner Willibald , Meitz Sarah , Mechtcheriakova Diana , Sobanov Yuri , Willmann Michael , Stockner Thomas , Spillner Edzard , Kunert Renate , Jensen-Jarolim Erika
Published: April 2023

PDF - 94K, Supplementary Methods.
Supplementary Figure 1 from PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer
Authors: Thanapprapasr Duangmani , Previs Rebecca A. , Hu Wei , Ivan Cristina , Armaiz-Pena Guillermo N. , Dorniak Piotr L. , Hansen Jean M. , Rupaimoole Rajesha , Huang Jie , Dalton Heather J. , Ali-Fehmi Rouba , Coleman Robert L. , Sood Anil K.
Published: April 2023

Mean mouse weights in orthotopic mouse models of uterine cancer.
Supplementary Table 3 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 67K, Full drug table of CMAP predictions corresponding to Figure 2.
Supplementary Table 2 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 67K, Gene list corresponding to the heapmap in Figure 2C.
Supplementary Table 1 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 44K, Gene list corresponding to the heatmap in Figure 1B.
Supplementary Table 1 from PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1)
Authors: Decker Sarah , Finter Johannes , Forde Aaron James , Kissel Sandra , Schwaller Juerg , Mack Thomas Sebastian , Kuhn Anabel , Gray Nathanael , Follo Marie , Jumaa Hassan , Burger Meike , Zirlik Katja , Pfeifer Dietmar , Miduturu Chandrasekhar V. , Eibel Hermann , Veelken Hendrik , Dierks Christine
Published: April 2023

PDF - 71K, Table describing patient characteristics regarding age, prognostic factors and WBC counts.
Supplementary Figures 1 through 3 from PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1)
Authors: Decker Sarah , Finter Johannes , Forde Aaron James , Kissel Sandra , Schwaller Juerg , Mack Thomas Sebastian , Kuhn Anabel , Gray Nathanael , Follo Marie , Jumaa Hassan , Burger Meike , Zirlik Katja , Pfeifer Dietmar , Miduturu Chandrasekhar V. , Eibel Hermann , Veelken Hendrik , Dierks Christine
Published: April 2023

PDf - 121K, Supplementary Figure 1. Percentage of viable cells with and without stromal support. Supplementary Figure 2. PIM inhibition reduces reexternalization of the CXCR4 receptor in MEC-1 cells. Supplementary Figure 3. Viability of CLL cells after 12 hours treatment with the PIM kinase inhibitor K00135.
Supplementary Figure 3 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 463K, Proteasome activity and baseline gene expression differences between sensitive and resistant mouse cell lines.
Data Supplement from Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells
Authors: Azarenko Olga , Smiyun Gregoriy , Mah Jeffrey , Wilson Leslie , Jordan Mary Ann
Published: April 2023

Supplementary Video 1. Control MCF7 cells were grown in the absence of the drugs for 24 hours. Microtubules are dynamic and alternate between growth and shortening.
Data Supplement from Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells
Authors: Azarenko Olga , Smiyun Gregoriy , Mah Jeffrey , Wilson Leslie , Jordan Mary Ann
Published: April 2023

Supplementary Video 2. MCF7 cells were incubated with 2 nmol/L Cabazitaxel for 24 hours. Microtubules display suppressed dynamics.
Data Supplement from Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells
Authors: Azarenko Olga , Smiyun Gregoriy , Mah Jeffrey , Wilson Leslie , Jordan Mary Ann
Published: April 2023

Supplementary Video 3. MCF7 cells were incubated with 2 nmol/L Docetaxel for 24 hours. Microtubules display suppressed dynamics.
Supplementary Materials and Methods from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Authors: Loddick Sarah A. , Ross Sarah J. , Thomason Andrew G. , Robinson David M. , Walker Graeme E. , Dunkley Tom P.J. , Brave Sandra R. , Broadbent Nicola , Stratton Natalie C. , Trueman Dawn , Mouchet Elizabeth , Shaheen Fadhel S. , Jacobs Vivien N. , Cumberbatch Marie , Wilson Joanne , Jones Rhys D.O. , Bradbury Robert H. , Rabow Alfred , Gaughan Luke , Womack Chris , Barry Simon T. , Robson Craig N. , Critchlow Susan E. , Wedge Stephen R. , Brooks A. Nigel
Published: April 2023

PDF - 56KB, Supplementary methods detailing Relative peptide quantification by selected reaction monitoring (SRM)using mass spectrometry
Supplementary Figure Legends from AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Authors: Loddick Sarah A. , Ross Sarah J. , Thomason Andrew G. , Robinson David M. , Walker Graeme E. , Dunkley Tom P.J. , Brave Sandra R. , Broadbent Nicola , Stratton Natalie C. , Trueman Dawn , Mouchet Elizabeth , Shaheen Fadhel S. , Jacobs Vivien N. , Cumberbatch Marie , Wilson Joanne , Jones Rhys D.O. , Bradbury Robert H. , Rabow Alfred , Gaughan Luke , Womack Chris , Barry Simon T. , Robson Craig N. , Critchlow Susan E. , Wedge Stephen R. , Brooks A. Nigel
Published: April 2023

PDF - 71KB
Supplementary Table 1 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 51K, Analysis of Variance tables. Degrees of freedom (Df), sum of squares (SS), mean sum of squares (Mean SS) and corresponding F statistic and p-value are shown.
Supplementary Figure 3 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 27K, Representative graphs mean of cell survival (in percentages) for each combination of Dovitinib and ICI. Confidence intervals as estimated from the linear models are shown. Experiments were performed, at least, 3 times on 3 independent days.
Supplementary Table 2 from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 61KB, Western Blot primary antibody.
Supplementary Figure Legend from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 86KB, Legends for Supplementary Figures S1-S3.
Supplementary Figure 3 from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 3658KB, Supplementary Figure S3. Downregulation of MAP4K4 reverses the malignant behavior of pancreatic cancer cell lines. (A) The MAP4K4 expression was downregulated after treated with its siRNA determined by SYBR Green qRT-PCR (left) and western blot (right). (B) Knockdown of MAP4K4 suppressed the proliferation of PANC-1 and MiaPaCa-2 cells. (C) Downregulation of MAP4K4 weakened the ability of cell clonogenicity. (D) The cell invasion ability was measured at 48 h after cells seeded in chambers. Silencing of MAP4K4 decreased the ability of cell invasion. (E) Cell cycle was examined by flow cytometry. Compared to NC groups, cell cycle in siRNA-MAP4K4 groups was blocked at G1 phase. (F) The percentage of apoptotic cells increased through downregulation of MAP4K4 in pancreatic cancer cell lines. (G) Silencing of MAP4K4 increased chemosensitivity to 5-Fu and Gemcitabine based on IC50 data. (H) Western blot assay illustrated that after treated with MAP4K4 siRNA, MMP-2, cyclinD1 and Bcl-2 were downregulated while Bax was upregulated. But the changes of MMP-9 were not so significant. *P<0.05, **P<0.01.
Supplementary Figure 2 from miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Authors: Zhao Gang , Wang Bo , Liu Yang , Zhang Jun-gang , Deng Shi-chang , Qin Qi , Tian Kui , Li Xiang , Zhu Shuai , Niu Yi , Gong Qiong , Wang Chun-you
Published: April 2023

PDF - 1052KB, Supplementary Figure S2. Inhibition of miR-141 upregulates MAP4K4 and promotes cell growth and invasion. (A) MiR-141 expression was downregulated after treated with miR-141 inhibitor. (B) Inhibition of miR-141 promoted the proliferation of PANC-1 cells by MTT assay. (C) Downregulation of miR-141 improved clonogenicity ability of PANC-1. (D) Invasion ability of PANC-1 cells was enhanced after decreasing of miR-141 expression. (E) MMP-2 and MMP-9 were upregulated after inhibition of miR-141 in PANC-1 by western blot analysis. *P<0.05, **P<0.01.
Supplementary Figures S1-S8 from Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer
Authors: Senkowski Wojciech , Zhang Xiaonan , Olofsson Maria Hägg , Isacson Ruben , Höglund Urban , Gustafsson Mats , Nygren Peter , Linder Stig , Larsson Rolf , Fryknäs Mårten
Published: April 2023

Supplementary Figures S1-S8. S1. Glucose concentration and pH in spheroid culture medium; S2. Dose-response and time-course experiment; S3. GFP-based and TOX8 assay comparison; S4. HT-29 spheroid-based clonogenic assay; S5. Final hit compounds' effects in spheroids formed with or without medium change S6. Nitazoxanide and tizoxanide effects comparison; S7. Nitazoxanide and irinotecan combination in clonogenic assay; S8. CD44 IHC staining.
Supplementary Table 1 and 2 from Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
Authors: Hisamatsu Takeshi , Mabuchi Seiji , Matsumoto Yuri , Kawano Mahiru , Sasano Tomoyuki , Takahashi Ryoko , Sawada Kenjiro , Ito Kimihiko , Kurachi Hirohisa , Schilder Russell J. , Testa Joseph R. , Kimura Tadashi
Published: April 2023

Supplementary Table 1 and 2 - PDF file 42K, Supplemental Table 1. Phospho-mTOR and Rictor immunoreactivity in CCCs and SACs. Supplemental Table 2. Effects of AZD8055 or RAD001 on cell cycle progression
Supplementary Materials and Methods from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas
Authors: Bai Xue-Li , Zhang Qi , Ye Long-Yun , Hu Qi-Da , Fu Qi-Han , Zhi Xiao , Su Wei , Su Ri-Ga , Ma Tao , Chen Wei , Xie Shang-Zhi , Chen Cong-Lin , Liang Ting-Bo
Published: April 2023

PDF - 169K, Supplementary Materials and Methods.
Supplementary Figure 1 from Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
Authors: Hisamatsu Takeshi , Mabuchi Seiji , Matsumoto Yuri , Kawano Mahiru , Sasano Tomoyuki , Takahashi Ryoko , Sawada Kenjiro , Ito Kimihiko , Kurachi Hirohisa , Schilder Russell J. , Testa Joseph R. , Kimura Tadashi
Published: April 2023

Supplementary Figure 1 - PDF file 46K, Establishment of RAD001-resistant variant cell lines
Supplementary Figure Legends from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 71K, Legends to Supplementary Figures 1 through 8.